Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Trogarzonon Apr 05, 2023 4:48pm
181 Views
Post# 35381898

Horrible markets for biotechs

Horrible markets for biotechsApart from Thera's stock being a total s..t show, these markets for small cap and biotech specilally are something of historical proportions.  Thera lived trough 30 years of being public and wend to 12$ a couple of times for no good reason and to 19 cents for better ones but this time whatever the outcome of the pipeline, well it's plain absurdity.  I have to agree with our friend going ape sh t about shorts, trolls and market manipulator.  The company used to have supporters like the Caisse and good retail base that made every past episodes less painful.  This time around they scrapped any relation that was left with their long time retail shareholders and the Big boys ain't showing lot of support for their cause by the way we keep loosing 5% o 10% on a 25k volume.  It's part markets, market participants but on the other hand they haven't managed to put in place an adequate base of large shareholders to back them in difficult times.  Working on a buyout on the cheap is not the same as long term beleivers.
<< Previous
Bullboard Posts
Next >>